emedicine.medscape.com

Amebiasis: Background, Pathophysiology, Etiology

  • ️Invalid Date

Background

Amebiasis is an infection primarily caused by the protozoan parasite Entamoeba histolytica. [1] It is mainly transmitted through the fecal-oral route, but also can be spread sexually via oral-anal contact. While many individuals infected with this parasite do not show symptoms, those who do may experience a range of issues from mild diarrhea to severe dysentery. In certain cases, the infection can result in extraintestinal complications, including liver abscesses and, in rare instances, brain abscesses.

Diagnosis involves identifying E histolytica in stool samples, which can be confirmed through immunoassays that detect specific antigens or through serological tests if extraintestinal disease is suspected. For symptomatic patients, treatment generally includes oral medications such as tinidazole, metronidazole, secnidazole, or ornidazole, followed by paromomycin or another drug that targets cysts in the colon. This protozoan is found globally, and another species, Entamoeba dispar, has also been noted as a potential cause of amebic liver abscesses. The highest rates of amebiasis are observed in developing countries, where inadequate sanitation and insufficient barriers between human feces and food and water supplies contribute to its spread.

Trichrome stain of Entamoeba histolytica trophozoi

Trichrome stain of Entamoeba histolytica trophozoites in amebiasis. Two diagnostic characteristics are observed. Two trophozoites have ingested erythrocytes, and all 3 have nuclei with small, centrally located karyosomes.

Although most cases of amebiasis are asymptomatic, dysentery and invasive extraintestinal disease can occur. Chronic non-dysenteric colitis is the most frequent form of amebiasis in people of all ages. [2]   Amebic liver abscess is the most common manifestation of invasive amebiasis, but other organs can also be involved, including pleuropulmonary, cardiac, cerebral, renal, genitourinary, peritoneal, and cutaneous sites. In developed countries, amebiasis primarily affects migrants from and travelers to endemic regions, men who have sex with men, and immunosuppressed or institutionalized individuals.

The National Institute of Allergy and Infectious Diseases (NIAID) has classified E histolytica as a category B biodefense pathogen because of its low infectious dose, environmental stability, resistance to chlorine, and ease of dissemination through contamination of food and water supplies. [3]

E histolytica is transmitted via ingestion of the cystic form (infective stage) of the protozoa. Viable in the environment for weeks to months, cysts can be found in fecally contaminated soil, fertilizer, or water or on the contaminated hands of food handlers. Fecal-oral transmission can also occur in the setting of anal sexual practices or direct rectal inoculation through colonic irrigation devices.

Excystation then occurs in the terminal ileum or colon, resulting in trophozoites (invasive form). The trophozoites can penetrate and invade the colonic mucosal barrier, leading to tissue destruction, secretory bloody diarrhea, and colitis resembling inflammatory bowel disease. In addition, the trophozoites can spread hematogenously via the portal circulation to the liver or even to more distant organs (see Pathophysiology).

Life cycle of amebiasis (Entamoeba histolytica). C

Life cycle of amebiasis (Entamoeba histolytica). Courtesy of the Centers for Disease Control and Prevention (CDC).

E histolytica is capable of causing a spectrum of illnesses (see Presentation). Intestinal conditions resulting from E histolytica infection include the following:

  • Asymptomatic infection

  • Symptomatic noninvasive infection

  • Acute proctocolitis (dysentery)

  • Fulminant colitis with perforation

  • Toxic megacolon

  • Chronic nondysenteric colitis

  • Ameboma

  • Perianal ulceration

  • Rectovaginal fistulae

Extraintestinal conditions resulting from E histolytica infection include the following:

  • Liver abscess

  • Pleuropulmonary disease

  • Peritonitis

  • Pericarditis

  • Brain abscess

  • Genitourinary disease

Laboratory diagnosis of amebiasis is made by demonstrating the organism or by employing immunologic techniques. In addition to standard blood tests, other laboratory studies employed for diagnosis include microscopy, culture, serologic testing, and polymerase chain reaction (PCR) assay (see Workup).

Treatment of amebiasis includes pharmacologic therapy, surgical intervention, and preventive measures, as appropriate (see Treatment). Most individuals with amebiasis may be treated on an outpatient basis, though several clinical scenarios may favor inpatient care.

See Common Intestinal Parasites, a Critical Images slideshow, to help make an accurate diagnosis.

eMedicine Logo

Pathophysiology

E histolytica is a pseudopod-forming, nonflagellated protozoal parasite that causes proteolysis and tissue lysis (hence the species name) and can induce host-cell apoptosis. Humans and perhaps nonhuman primates are the only natural hosts.

Ingestion of E histolytica cysts (see the first image below) from the environment is followed by excystation in the terminal ileum or colon to form highly motile trophozoites (see the second image below). Upon colonization of the colonic mucosa, the trophozoite may encyst and is then excreted in the feces, or it may invade the intestinal mucosal barrier and gain access to the bloodstream, whereby it is disseminated to the liver, lung, and other sites. Excreted cysts reach the environment to complete the cycle.

Disease may be caused by only a small number of cysts, but the processes of encystation and excystation are poorly understood.

Entamoeba histolytica cyst. Image courtesy of Cent

Entamoeba histolytica cyst. Image courtesy of Centers for Disease Control and Prevention.

Entamoeba histolytica trophozoite. Image courtesy

Entamoeba histolytica trophozoite. Image courtesy of Centers for Disease Control and Prevention.

Adherence and Immune Response

The adherence of trophozoites to colonic epithelial cells seems to be mediated by a galactose/N-acetylgalactosamine (GAL/GalNAc)–specific lectin, [4, 5, 6]  a 260-kd surface protein containing a 170-kd subunit and a 35-kd subunit. A mucosal immunoglobulin A (IgA) response against this lectin can result in fewer recurrent infections. [7]

Cytolytic Mechanisms

Both lytic and apoptotic pathways have been described. Cytolysis can be undertaken by amebapores, a family of peptides capable of forming pores in lipid bilayers. [4]  Furthermore, in animal models of liver abscess, trophozoites induced apoptosis via a non-Fas and non–tumor necrosis factor (TNF)-α1 receptor pathway. [8]  The amebapores, at sublytic concentrations, also can induce apoptosis.

Role of Cysteine Proteinases

Cysteine proteinases have been directly implicated in invasion and inflammation of the gut and may amplify interleukin (IL)-1–mediated inflammation by mimicking the action of human IL-1–converting enzyme, cleaving IL-1 precursor to its active form. [4, 9]  The cysteine proteinases can also cleave and inactivate the anaphylatoxins C3a and C5a, as well as IgA and immunoglobulin G (IgG). [10, 11]

Transmembrane Kinases and Virulence

E histolytica possesses about 100 putative transmembrane kinases (TMKs), which are commonly divided into 9 subgroups. Of these, EhTMKB1-9 is expressed in proliferating trophozoites and induced by serum. In an animal model, it was found to be involved in phagocytosis and to play a role as a virulence factor in amebic colitis. [12]  These findings suggest that TMKs such as EhTMKB1-9 may be attractive targets for future drug development.

Inflammatory Mediators and Immune Response

Epithelial cells also produce various inflammatory mediators, including IL-1β, IL-8, and cyclooxygenase (COX)-2, leading to the attraction of neutrophils and macrophages. [13, 14]  Corticosteroid therapy is known to worsen the clinical outcome, possibly because of its blunting effect on this innate immune response.

Host Defense Mechanisms

Additional host defenses, including the complement system, could be inhibited directly by the trophozoites, as is suggested by the finding that a region of the GAL/GalNAc–specific lectin showed antigenic crossreactivity with CD59, a membrane inhibitor of the C5b-9 attack complex in human red blood cells. [15]

Spread of Amebiasis to the Liver

Spread of amebiasis to the liver occurs via the portal blood. The pathogenic strains evade the complement-mediated lysis in the bloodstream. Trophozoites that reach the liver create unique abscesses with well-circumscribed regions of dead hepatocytes surrounded by few inflammatory cells and trophozoites and unaffected hepatocytes. These findings suggest that E histolytica organisms are able to kill hepatocytes without direct contact. [4]

Immune Responses in Amebic Liver Abscess

Serum antibodies in patients with amebic liver abscess develop in 7 days and persist for as long as 10 years. A mucosal IgA response to E histolytica occurs during invasive amebiasis; however, no evidence suggests that invasive amebiasis is increased in incidence or severity in patients with IgA deficiency.

Cell-Mediated Immunity

Cell-mediated immunity is important in limiting the disease and preventing recurrences. Antigen-specific blastogenic responses occur, leading to production of lymphokines, including interferon-delta, which activates the killing of E histolytica trophozoites by the macrophages. This killing depends on contact, oxidative pathways, nonoxidative pathways, and nitric oxide (NO). Lymphokines, such as TNF-α, are capable of activating the amebicidal activity of neutrophils. Incubation of CD8+ lymphocytes with E histolytica antigens in vitro elicits cytotoxic T-cell activity against the trophozoites. During acute invasive amebiasis, T-cell response to E histolytica antigens is depressed by a parasite-induced serum factor.

eMedicine Logo

Etiology

Amebiasis is a parasitic infection caused by the protozoal organism E histolytica, which can give rise both to intestinal disease (eg, colitis) and to various extraintestinal manifestations, including liver abscess (most common) and pleuropulmonary, cardiac, and cerebral dissemination.

The genus Entamoeba contains many species, some of which (ie, E histolytica, Entamoeba dispar, Entamoeba moshkovskii, Entamoeba bangladeshi, Entamoeba polecki, Entamoeba coli, and Entamoeba hartmanni) can reside in the human interstitial lumen. Of these, E histolytica is the only one definitely associated with disease, although a 2012 report suggested E moshkovskii to be the causative agent of diarrhea in infants. [16, 17] Although E dispar and E histolytica cannot be differentiated by means of direct examination, molecular techniques have demonstrated that they are indeed two different species, with E dispar being commensal (as in patients with HIV infection) and E histolytica pathogenic. [16]

It is currently believed that many individuals with Entamoeba infections are actually colonized with E dispar, which appears to be 10 times more common than E histolytica [16] ; however, in certain regions (eg, Brazil and Egypt), asymptomatic E dispar and E histolytica infections are equally prevalent. [4] In Western countries, approximately 20-30% of men who have sex with men are colonized with E dispar. [16]

E histolytica is transmitted primarily through the fecal-oral route. Infective cysts can be found in fecally contaminated food and water supplies and contaminated hands of food handlers. Sexual transmission is possible, especially in the setting of oral-anal practices (anilingus). [18] Poor nutrition, through its effect on immunity, has been found to be a risk factor for amebiasis. [19]

eMedicine Logo

Epidemiology

United States statistics

The overall prevalence of amebiasis in the United States is approximately 4%. E dispar infection, which always is asymptomatic, is 10 times more common than E histolytica infection. Moreover, only 10% of E histolytica infections cause invasive disease. Therefore, only 1% of persons with stool microscopy findings that reveal Entamoeba develop symptomatic amebiasis.

In the United States, amebiasis is most frequently observed in the following [20] :

  • Individuals who have traveled to tropical regions with inadequate sanitation

  • Immigrants from tropical countries where sanitation is lacking

  • Residents of facilities with substandard sanitary conditions

  • Individuals who engage in anal sex

An increased prevalence of amebiasis is noted in institutionalized persons (especially those with intellectual disabilities), male homosexuals, and persons living in communal settings.

Travelers to endemic areas are at risk for infection and represent most US cases. It is estimated that 14 of every 1,000 returning travelers with diarrhea have amebiasis, which accounts for 12.5% of all microbiologically confirmed cases. [21] Travel to South Asia, the Middle East, and South America poses the highest risk. Amebic liver abscess has been reported after a median duration of 3 months but may occur years later.

The US national death certificate data from 1990 to 2007 identified 134 deaths from amebiasis. A declining trend of deaths has been noted, with a current rate of 5 deaths per year. [22] More than 40% of reported deaths occurred in residents of California and Texas, with US-born persons accounting for most amebiasis deaths. [23]

International statistics

The parasite E histolytica is found worldwide, but the majority of infections occur in Central America, western South America, western and southern Africa, India, and specific regions of South Asia. In countries with safe food and water supplies, most cases are reported among recent immigrants and travelers returning from endemic areas.

It is estimated that approximately 50 million individuals globally develop amebic colitis or extraintestinal disease each year, resulting in as many as 73,000 fatalities attributed to the infection. [1]

Previous estimates of E histolytica infections, which relied on stool examinations for ova and parasites, have proven inaccurate, as these tests cannot distinguish E histolytica from E dispar and E moshkovskii. In developing countries, the prevalence of E histolytica, as determined by enzyme-linked immunosorbent assay (ELISA) or polymerase chain reaction (PCR) testing of stool samples from asymptomatic individuals, ranges from 1% to 21%. Estimates suggest that around 500 million people with Entamoeba infections are colonized by E dispar. [16]

The prevalence of Entamoeba infection can reach as high as 50% in certain regions of Central and South America, Africa, and Asia. [24]  Seroprevalence studies in Mexico have shown that over 8% of the population tested positive for E histolytica. [25]  In endemic areas, up to 25% of patients may carry antibodies to E histolytica due to prior infections, which are often asymptomatic. The prevalence of asymptomatic E histolytica infections appears to vary by region; for instance, in Brazil, it may be as high as 11%.

In Egypt, 38% of individuals presenting with acute diarrhea at outpatient clinics were diagnosed with amebic colitis. [4]  A study in Bangladesh found that preschool children experienced an average of 0.09 episodes of E histolytica-associated diarrhea and 0.03 episodes of amebic dysentery each year. In Hue City, Vietnam, the annual incidence of amebic liver abscess was reported to be 21 cases per 100,000 inhabitants. [26]

An epidemiological study conducted in Mexico City indicated that 9% of the population was infected with E histolytica in the 5 to 10 years prior to the study. Contributing factors to fecal-oral transmission included poor education, poverty, overcrowding, contaminated water supplies, and unsanitary conditions.

Several studies have explored the association between amebiasis and AIDS. [27, 28, 29, 30, 31, 32]  The impact of the AIDS pandemic on the prevalence of invasive amebiasis remains a topic of debate. While some reports suggest that invasive amebiasis does not increase among patients with HIV infection, [33]  others indicate that amebic liver abscess is becoming a significant parasitic infection in individuals with HIV in both disease-endemic and non-endemic areas. [34]

Among 31 patients with amebic liver abscess at Seoul National University Hospital from 1990 to 2005, 10 (32%) were found to be HIV-positive. [35]  Additionally, a case-control study of individuals seeking voluntary counseling and testing for HIV infection identified several risk factors for amebiasis, including homosexual activity, fecal-oral contamination, lower educational achievement, and older age. [36]

Age-related demographics

Symptomatic intestinal amebiasis occurs in all age groups. Liver abscesses due to amebiasis are 10 times more frequent in adults than in children. Very young children seem to be predisposed to fulminant colitis. [37]

Sex-related demographics

Amebic colitis affects both sexes equally. [4] However, invasive amebiasis is much more common in adult males than in females. In particular, amebic liver abscess is 7-12 times more common in men than in women, with a predominance among men aged 18-50 years. The reason for this disparity is unknown, though hormonal effects may be implicated, as the prevalence of amebic liver abscess also is increased among postmenopausal women. Alcohol also may be an important risk factor. [38]

Among prepubertal children, amebic liver abscess is equally common in both sexes. [4] Acuna-Soto et al noted that asymptomatic E histolytica infection is distributed equally between sexes. [39] Therefore, the higher proportion of adult males with invasive amebiasis may be due to a male susceptibility to invasive disease.

Race-related demographics

In Japan and Taiwan, HIV seropositivity is a risk factor for invasive extraintestinal amebiasis. [34] This association has not been observed elsewhere. Among HIV-positive patients, homosexual intercourse, and not immunosuppressed status, seems to be a risk factor for amebic colitis. [40]

eMedicine Logo

Prognosis

Amebic infections can lead to significant morbidity while causing variable mortality. In terms of protozoan-associated mortality, amebiasis is second only to malaria. The severity of amebiasis is increased in the following groups:

  • Children, especially neonates

  • Pregnant and postpartum women

  • Those using corticosteroids

  • Those with malignancies

  • Malnourished individuals

Intestinal infections due to amebiasis generally respond well to appropriate therapy, though it should be kept in mind that previous infection and treatment will not protect against future colonization or recurrent invasive amebiasis.

Asymptomatic intestinal amebiasis occurs in 90% of infected individuals. However, only 4%-10% of individuals with asymptomatic amebiasis who were monitored for 1 year eventually developed colitis or extraintestinal disease. [16]

With the introduction of effective medical treatment, mortality has fallen below 1% for patients with uncomplicated amebic liver abscess. However, amebic liver abscess can be complicated by sudden intraperitoneal rupture in 2-7% of patients, and this complication leads to a higher mortality. [4]

Case-fatality rates associated with amebic colitis range from 1.9% to 9.1%. Amebic colitis evolves to fulminant necrotizing colitis or rupture in approximately 0.5% of cases; in such cases, mortality may exceeds 40% [41] or even, according to some reports, 50%.

Pleuropulmonary amebiasis has a 15%-20% mortality rate. Amebic pericarditis has a case-fatality rate of 40%. Cerebral amebiasis carries a very high mortality (90%).

A study of 134 deaths in the United States from 1990 to 2007 found that mortality was highest in men, Hispanics, Asian/Pacific Islanders, and people aged 75 years or older. [23] An association with HIV infection was also observed. Although deaths declined during the course of the study, more than 40% occurred in California and Texas. US-born persons accounted for the majority of amebiasis deaths; however, all of the fatalities in Asian/Pacific Islanders and 60% of the deaths in Hispanics were in foreign-born individuals.

eMedicine Logo

Patient Education

Individuals traveling to endemic areas should be advised on practices that minimize the risk of amebiasis, such as the following [20, 1] :

  • Avoid drinking contaminated water; use bottled water while traveling if possible

  • If local water is to be drunk, purify it by (a) boiling it for more than 1 minute, (b) using 0.22 µm filtration, or (c) iodinating it with tetraglycine hydroperiodide

  • Avoid eating raw fruits and salads, which are difficult to sterilize; eat only cooked food or self-peeled fruits if possible

  • Wash uncooked vegetables and soak them in acetic acid or vinegar for 10-15 minutes

eMedicine Logo

  1. Marie D, Petri WA. Amebiasis. Porter RE. The Merck Manual of Diagnosis and Therapy. Rahway, NJ: Merck & Co Inc; May 2023. [Full Text].

  2. Morán P, Serrano-Vázquez A, Rojas-Velázquez L, González E, Pérez-Juárez H, Hernández EG, et al. Amoebiasis: Advances in Diagnosis, Treatment, Immunology Features and the Interaction with the Intestinal Ecosystem. Int J Mol Sci. 2023 Jul 21. 24 (14):[QxMD MEDLINE Link].

  3. Shirley DT, Farr L, Watanabe K, Moonah S. A Review of the Global Burden, New Diagnostics, and Current Therapeutics for Amebiasis. Open Forum Infect Dis. 2018 Jul. 5 (7):ofy161. [QxMD MEDLINE Link].

  4. Stanley SL Jr. Amoebiasis. Lancet. 2003 Mar 22. 361(9362):1025-34. [QxMD MEDLINE Link].

  5. Ravdin JI, Stanley P, Murphy CF, Petri WA Jr. Characterization of cell surface carbohydrate receptors for Entamoeba histolytica adherence lectin. Infect Immun. 1989 Jul. 57(7):2179-86. [QxMD MEDLINE Link]. [Full Text].

  6. Ximénez C, Cerritos R, Rojas L, Dolabella S, Morán P, Shibayama M, et al. Human amebiasis: breaking the paradigm?. Int J Environ Res Public Health. 2010 Mar. 7(3):1105-20. [QxMD MEDLINE Link]. [Full Text].

  7. Haque R, Mondal D, Duggal P, Kabir M, Roy S, Farr BM, et al. Entamoeba histolytica infection in children and protection from subsequent amebiasis. Infect Immun. 2006 Feb. 74(2):904-9. [QxMD MEDLINE Link]. [Full Text].

  8. Seydel KB, Stanley SL Jr. Entamoeba histolytica induces host cell death in amebic liver abscess by a non-Fas-dependent, non-tumor necrosis factor alpha-dependent pathway of apoptosis. Infect Immun. 1998 Jun. 66(6):2980-3. [QxMD MEDLINE Link]. [Full Text].

  9. Que X, Reed SL. Cysteine proteinases and the pathogenesis of amebiasis. Clin Microbiol Rev. 2000 Apr. 13(2):196-206. [QxMD MEDLINE Link]. [Full Text].

  10. Kelsall BL, Ravdin JI. Degradation of human IgA by Entamoeba histolytica. J Infect Dis. 1993 Nov. 168(5):1319-22. [QxMD MEDLINE Link].

  11. Reed SL, Keene WE, McKerrow JH, Gigli I. Cleavage of C3 by a neutral cysteine proteinase of Entamoeba histolytica. J Immunol. 1989 Jul 1. 143(1):189-95. [QxMD MEDLINE Link].

  12. Abhyankar MM, Shrimal S, Gilchrist CA, Bhattacharya A, Petri WA Jr. The Entamoeba histolytica serum-inducible transmembrane kinase EhTMKB1-9 is involved in intestinal amebiasis. Int J Parasitol Drugs Drug Resist. 2012 Dec. 2:243-248. [QxMD MEDLINE Link]. [Full Text].

  13. Seydel KB, Li E, Swanson PE, Stanley SL Jr. Human intestinal epithelial cells produce proinflammatory cytokines in response to infection in a SCID mouse-human intestinal xenograft model of amebiasis. Infect Immun. 1997 May. 65(5):1631-9. [QxMD MEDLINE Link]. [Full Text].

  14. Stenson WF, Zhang Z, Riehl T, Stanley SL Jr. Amebic infection in the human colon induces cyclooxygenase-2. Infect Immun. 2001 May. 69(5):3382-8. [QxMD MEDLINE Link]. [Full Text].

  15. Braga LL, Ninomiya H, McCoy JJ, Eacker S, Wiedmer T, Pham C, et al. Inhibition of the complement membrane attack complex by the galactose-specific adhesion of Entamoeba histolytica. J Clin Invest. 1992 Sep. 90(3):1131-7. [QxMD MEDLINE Link]. [Full Text].

  16. Fotedar R, Stark D, Beebe N, Marriott D, Ellis J, Harkness J. Laboratory diagnostic techniques for Entamoeba species. Clin Microbiol Rev. 2007 Jul. 20(3):511-32, table of contents. [QxMD MEDLINE Link]. [Full Text].

  17. Shimokawa C, Kabir M, Taniuchi M, Mondal D, Kobayashi S, Ali IK, et al. Entamoeba moshkovskii is associated with diarrhea in infants and causes diarrhea and colitis in mice. J Infect Dis. 2012 Sep 1. 206 (5):744-51. [QxMD MEDLINE Link].

  18. Billet AC, Salmon Rousseau A, Piroth L, Martins C. An underestimated sexually transmitted infection: amoebiasis. BMJ Case Rep. 2019 May 10. 12 (5):[QxMD MEDLINE Link].

  19. Verkerke HP, Petri WA Jr, Marie CS. The dynamic interdependence of amebiasis, innate immunity, and undernutrition. Semin Immunopathol. 2012 Nov. 34(6):771-85. [QxMD MEDLINE Link]. [Full Text].

  20. CDC. About Amebiasis. Centers for Disease Control and Prevention. Available at https://www.cdc.gov/amebiasis/about/index.html. May 2, 2024; Accessed: December 12, 2024.

  21. Swaminathan A, Torresi J, Schlagenhauf P, Thursky K, Wilder-Smith A, Connor BA, et al. A global study of pathogens and host risk factors associated with infectious gastrointestinal disease in returned international travellers. J Infect. 2009 Jul. 59 (1):19-27. [QxMD MEDLINE Link].

  22. Gunther J, Shafir S, Bristow B, Sorvillo F. Short report: Amebiasis-related mortality among United States residents, 1990-2007. Am J Trop Med Hyg. 2011 Dec. 85 (6):1038-40. [QxMD MEDLINE Link].

  23. Gunther J, Shafir S, Bristow B, Sorvillo F. Short report: Amebiasis-related mortality among United States residents, 1990-2007. Am J Trop Med Hyg. 2011 Dec. 85(6):1038-40. [QxMD MEDLINE Link]. [Full Text].

  24. Tengku SA, Norhayati M. Public health and clinical importance of amoebiasis in Malaysia: a review. Trop Biomed. 2011 Aug. 28(2):194-222. [QxMD MEDLINE Link].

  25. Caballero-Salcedo A, Viveros-Rogel M, Salvatierra B, Tapia-Conyer R, Sepulveda-Amor J, Gutierrez G, et al. Seroepidemiology of amebiasis in Mexico. Am J Trop Med Hyg. 1994 Apr. 50(4):412-9. [QxMD MEDLINE Link].

  26. Blessmann J, Van Linh P, Nu PA, Thi HD, Muller-Myhsok B, Buss H, et al. Epidemiology of amebiasis in a region of high incidence of amebic liver abscess in central Vietnam. Am J Trop Med Hyg. 2002 May. 66(5):578-83. [QxMD MEDLINE Link].

  27. Bowley DM, Loveland J, Omar T, Pitcher GJ. Human immunodeficiency virus infection and amebiasis. Pediatr Infect Dis J. 2006 Dec. 25(12):1192-3. [QxMD MEDLINE Link].

  28. Brindicci G, Picciarelli C, Fumarola L, Carbonara S, Stano F, Ciracì E, et al. Amoebic hepatic abscesses in an HIV-positive patient. AIDS Patient Care STDS. 2006 Sep. 20(9):606-11. [QxMD MEDLINE Link].

  29. Chen Y, Zhang Y, Yang B, Qi T, Lu H, Cheng X, et al. Seroprevalence of Entamoeba histolytica infection in HIV-infected patients in China. Am J Trop Med Hyg. 2007 Nov. 77(5):825-8. [QxMD MEDLINE Link]. [Full Text].

  30. Hsu MS, Hsieh SM, Chen MY, Hung CC, Chang SC. Association between amebic liver abscess and human immunodeficiency virus infection in Taiwanese subjects. BMC Infect Dis. 2008 Apr 16. 8:48. [QxMD MEDLINE Link]. [Full Text].

  31. Karp CL, Auwaerter PG. Coinfection with HIV and tropical infectious diseases. I. Protozoal pathogens. Clin Infect Dis. 2007 Nov 1. 45(9):1208-13. [QxMD MEDLINE Link].

  32. Park WB, Choe PG, Jo JH, Kim SH, Bang JH, Kim HB, et al. Amebic liver abscess in HIV-infected patients, Republic of Korea. Emerg Infect Dis. 2007 Mar. 13(3):516-7. [QxMD MEDLINE Link]. [Full Text].

  33. Infection by human immunodeficiency virus-1 is not a risk factor for amebiasis. Am J Trop Med Hyg. 2006 Nov. 75(5):1023. [QxMD MEDLINE Link].

  34. Hung CC, Ji DD, Sun HY, Lee YT, Hsu SY, Chang SY, et al. Increased risk for Entamoeba histolytica infection and invasive amebiasis in HIV seropositive men who have sex with men in Taiwan. PLoS Negl Trop Dis. 2008 Feb 27. 2(2):e175. [QxMD MEDLINE Link]. [Full Text].

  35. Muzaffar J, Madan K, Sharma MP, Kar P. Randomized, single-blind, placebo-controlled multicenter trial to compare the efficacy and safety of metronidazole and satranidazole in patients with amebic liver abscess. Dig Dis Sci. 2006 Dec. 51(12):2270-3. [QxMD MEDLINE Link].

  36. Hung CC, Wu PY, Chang SY, Ji DD, Sun HY, Liu WC, et al. Amebiasis among persons who sought voluntary counseling and testing for human immunodeficiency virus infection: a case-control study. Am J Trop Med Hyg. 2011 Jan. 84(1):65-9. [QxMD MEDLINE Link]. [Full Text].

  37. Gupta S, Smith L, Diakiw A. Amebiasis and Amebic Liver Abscess in Children. Pediatr Clin North Am. 2022 Feb. 69 (1):79-97. [QxMD MEDLINE Link].

  38. Chandnani S, Udgirkar S, Jain SS, Sonthalia N, Contractor Q, Rathi PM, et al. Massive Lower Gastrointestinal Bleeding Due to Fulminant Necrotizing Amebic Colitis: A Diagnostic and Therapeutic Challenge. J Assoc Physicians India. 2019 Apr. 67 (4):79-81. [QxMD MEDLINE Link].

  39. Acuna-Soto R, Maguire JH, Wirth DF. Gender distribution in asymptomatic and invasive amebiasis. Am J Gastroenterol. 2000 May. 95(5):1277-83. [QxMD MEDLINE Link].

  40. Nagata N, Shimbo T, Akiyama J, Nakashima R, Nishimura S, Yada T. Risk factors for intestinal invasive amebiasis in Japan, 2003-2009. Emerg Infect Dis. 2012 May. 18(5):717-24. [QxMD MEDLINE Link].

  41. Aristizábal H, Acevedo J, Botero M. Fulminant amebic colitis. World J Surg. 1991 Mar-Apr. 15(2):216-21. [QxMD MEDLINE Link].

  42. Carrero JC, Reyes-López M, Serrano-Luna J, Shibayama M, Unzueta J, León-Sicairos N, et al. Intestinal amoebiasis: 160 years of its first detection and still remains as a health problem in developing countries. Int J Med Microbiol. 2020 Jan. 310 (1):151358. [QxMD MEDLINE Link].

  43. Andrade JE, Mederos R, Rivero H, Sendzischew MA, Soaita M, Robinson MJ, et al. Amebiasis presenting as acute appendicitis. South Med J. 2007 Nov. 100(11):1140-2. [QxMD MEDLINE Link].

  44. Goyal A, Goyal S, Gupta CR. Acute amoebic appendicitis: An unusual presentation of a usual infection. Indian J Pathol Microbiol. 2019 Jan-Mar. 62 (1):169-170. [QxMD MEDLINE Link].

  45. Bansal R, Natarajan S, Aron J. Amebic Colitis. Am J Med Sci. 2019 May. 357 (5):e15. [QxMD MEDLINE Link].

  46. Shirley DA, Moonah S. Fulminant Amebic Colitis after Corticosteroid Therapy: A Systematic Review. PLoS Negl Trop Dis. 2016 Jul. 10 (7):e0004879. [QxMD MEDLINE Link].

  47. Rao S, Solaymani-Mohammadi S, Petri WA Jr, Parker SK. Hepatic amebiasis: a reminder of the complications. Curr Opin Pediatr. 2009 Feb. 21(1):145-9. [QxMD MEDLINE Link]. [Full Text].

  48. Jain M, Jain J, Gupta S. Amebic liver abscess in children-Experience from Central India. Indian J Gastroenterol. 2016 May. 35 (3):248-9. [QxMD MEDLINE Link].

  49. Mohidin B, Green SF, Duggineni S. Amoebic liver abscess. QJM. 2018 Nov 1. 111 (11):821-822. [QxMD MEDLINE Link].

  50. Goswami A, Dadhich S, Bhargava N. Colonic involvement in amebic liver abscess: does site matter?. Ann Gastroenterol. 2014. 27(2):156-161. [QxMD MEDLINE Link]. [Full Text].

  51. Sodhi KS, Ojili V, Sakhuja V, Khandelwal N. Hepatic and inferior vena caval thrombosis: vascular complication of amebic liver abscess. J Emerg Med. 2008 Feb. 34(2):155-7. [QxMD MEDLINE Link].

  52. Silvestri V, Ngasala B. Hepatic aneurysm in patients with amoebic liver abscess. A review of cases in literature. Travel Med Infect Dis. 2022 Mar-Apr. 46:102274. [QxMD MEDLINE Link].

  53. Koesbandono, Utomo R, Lukito B, Treser J, Sindunata NA. Preoperative Transcatheter Arterial Embolization for Spontaneous Rupture of Huge Amebic Liver Abscess with Massive Intraperitoneal Hemorrhage. J Radiol Case Rep. 2023 Aug. 17 (8):38-48. [QxMD MEDLINE Link].

  54. Hardin RE, Ferzli GS, Zenilman ME, Gadangi PK, Bowne WB. Invasive amebiasis and ameboma formation presenting as a rectal mass: An uncommon case of malignant masquerade at a western medical center. World J Gastroenterol. 2007 Nov 14. 13(42):5659-61. [QxMD MEDLINE Link].

  55. Loulergue P, Mir O. Pleural empyema secondary to amebic liver abscess. Int J Infect Dis. 2009 May. 13(3):e135-6. [QxMD MEDLINE Link].

  56. Dhawan VK, Malik SK. Acute pneumonia in the right lower lobe. Chest. 1975 Mar. 67(3):346-7. [QxMD MEDLINE Link]. [Full Text].

  57. José Wagner Leonel TJ, Arruda AR, Coimbra PPA. Isolated amoebic brain abscess with excellent therapeutic response. Rev Soc Bras Med Trop. 2022. 55:e00502022. [QxMD MEDLINE Link].

  58. Otan E, Akbulut S, Kayaalp C. Amebic acute appendicitis: systematic review of 174 cases. World J Surg. 2013 Sep. 37(9):2061-73. [QxMD MEDLINE Link].

  59. Abd-Alla MD, Jackson TF, Gathiram V, el-Hawey AM, Ravdin JI. Differentiation of pathogenic Entamoeba histolytica infections from nonpathogenic infections by detection of galactose-inhibitable adherence protein antigen in sera and feces. J Clin Microbiol. 1993 Nov. 31(11):2845-50. [QxMD MEDLINE Link]. [Full Text].

  60. Haque R, Mollah NU, Ali IK, Alam K, Eubanks A, Lyerly D, et al. Diagnosis of amebic liver abscess and intestinal infection with the TechLab Entamoeba histolytica II antigen detection and antibody tests. J Clin Microbiol. 2000 Sep. 38(9):3235-9. [QxMD MEDLINE Link]. [Full Text].

  61. Helmy MM, Rashed LA, Abdel-Fattah HS. Detection and differentiation of Entamoeba histolytica and Entamoeba dispar isolates in clinical samples by PCR. J Egypt Soc Parasitol. 2007 Apr. 37(1):257-74. [QxMD MEDLINE Link].

  62. Singh A, Houpt E, Petri WA. Rapid Diagnosis of Intestinal Parasitic Protozoa, with a Focus on Entamoeba histolytica. Interdiscip Perspect Infect Dis. 2009. 2009:547090. [QxMD MEDLINE Link]. [Full Text].

  63. Tanyuksel M, Petri WA Jr. Laboratory diagnosis of amebiasis. Clin Microbiol Rev. 2003 Oct. 16(4):713-29. [QxMD MEDLINE Link]. [Full Text].

  64. Saidin S, Othman N, Noordin R. Update on laboratory diagnosis of amoebiasis. Eur J Clin Microbiol Infect Dis. 2019 Jan. 38 (1):15-38. [QxMD MEDLINE Link].

  65. Roy S, Kabir M, Mondal D, Ali IK, Petri WA Jr, Haque R. Real-time-PCR assay for diagnosis of Entamoeba histolytica infection. J Clin Microbiol. 2005 May. 43 (5):2168-72. [QxMD MEDLINE Link].

  66. Buss SN, Leber A, Chapin K, Fey PD, Bankowski MJ, Jones MK, et al. Multicenter evaluation of the BioFire FilmArray gastrointestinal panel for etiologic diagnosis of infectious gastroenteritis. J Clin Microbiol. 2015 Mar. 53 (3):915-25. [QxMD MEDLINE Link].

  67. Binnicker MJ. Multiplex Molecular Panels for Diagnosis of Gastrointestinal Infection: Performance, Result Interpretation, and Cost-Effectiveness. J Clin Microbiol. 2015 Dec. 53 (12):3723-8. [QxMD MEDLINE Link].

  68. Shamsuzzaman SM, Haque R, Hasin SK, Hashiguchi Y. Evaluation of indirect fluorescent antibody test and enzyme-linked immunosorbent assay for diagnosis of hepatic amebiasis in Bangladesh. J Parasitol. 2000 Jun. 86(3):611-5. [QxMD MEDLINE Link].

  69. Ahmad N, Khan M, Hoque MI, Haque R, Mondol D. Detection of Entamoeba histolytica DNA from liver abscess aspirate using polymerase chain reaction (PCR): a diagnostic tool for amoebic liver abscess. Bangladesh Med Res Counc Bull. 2007 Apr. 33(1):13-20. [QxMD MEDLINE Link].

  70. Fotedar R, Stark D, Beebe N, Marriott D, Ellis J, Harkness J. PCR detection of Entamoeba histolytica, Entamoeba dispar, and Entamoeba moshkovskii in stool samples from Sydney, Australia. J Clin Microbiol. 2007 Mar. 45(3):1035-7. [QxMD MEDLINE Link]. [Full Text].

  71. Khairnar K, Parija SC. A novel nested multiplex polymerase chain reaction (PCR) assay for differential detection of Entamoeba histolytica, E. moshkovskii and E. dispar DNA in stool samples. BMC Microbiol. 2007 May 24. 7:47. [QxMD MEDLINE Link]. [Full Text].

  72. Stark D, van Hal S, Fotedar R, Butcher A, Marriott D, Ellis J, et al. Comparison of stool antigen detection kits to PCR for diagnosis of amebiasis. J Clin Microbiol. 2008 May. 46(5):1678-81. [QxMD MEDLINE Link]. [Full Text].

  73. Singh P, Mirdha BR, Ahuja V, Singh S. Loop-mediated isothermal amplification (LAMP) assay for rapid detection of Entamoeba histolytica in amoebic liver abscess. World J Microbiol Biotechnol. 2013 Jan. 29(1):27-32. [QxMD MEDLINE Link].

  74. Khunger S, Mewara A, Kaur U, Duseja A, Ray P, Kalra N, et al. Real-time loop-mediated isothermal amplification (real-time LAMP) assay for rapid diagnosis of amoebic liver abscess. Trop Med Int Health. 2024 Feb. 29 (2):104-112. [QxMD MEDLINE Link].

  75. Arivalagan B, Vashisht R, Sharma A, Vidhale TA. Multiple amoebic liver abscesses with characteristic anchovy sauce aspirate. BMJ Case Rep. 2023 Oct 10. 16 (10):[QxMD MEDLINE Link].

  76. Tanaka E, Tashiro Y, Kotake A, Takeyama N, Umemoto T, Nagahama M, et al. Spectrum of CT findings in amebic colitis. Jpn J Radiol. 2021 Jun. 39 (6):558-563. [QxMD MEDLINE Link].

  77. Misra SP, Misra V, Dwivedi M. Ileocecal masses in patients with amebic liver abscess: etiology and management. World J Gastroenterol. 2006 Mar 28. 12(12):1933-6. [QxMD MEDLINE Link].

  78. Nagata N, Shimbo T, Akiyama J, Nakashima R, Niikura R, Nishimura S, et al. Predictive value of endoscopic findings in the diagnosis of active intestinal amebiasis. Endoscopy. 2012 Apr. 44(4):425-8. [QxMD MEDLINE Link].

  79. Gonzales ML, Dans LF, Martinez EG. Antiamoebic drugs for treating amoebic colitis. Cochrane Database Syst Rev. 2009 Apr 15. CD006085. [QxMD MEDLINE Link].

  80. Petri WA Jr, Singh U. Diagnosis and management of amebiasis. Clin Infect Dis. 1999 Nov. 29(5):1117-25. [QxMD MEDLINE Link].

  81. Salles JM, Salles MJ, Moraes LA, Silva MC. Invasive amebiasis: an update on diagnosis and management. Expert Rev Anti Infect Ther. 2007 Oct. 5(5):893-901. [QxMD MEDLINE Link].

  82. Kimura M, Nakamura T, Nawa Y. Experience with intravenous metronidazole to treat moderate-to-severe amebiasis in Japan. Am J Trop Med Hyg. 2007 Aug. 77(2):381-5. [QxMD MEDLINE Link].

  83. Moon TD, Oberhelman RA. Antiparasitic therapy in children. Pediatr Clin North Am. 2005 Jun. 52(3):917-48, viii. [QxMD MEDLINE Link].

  84. Gonzales MLM, Dans LF, Sio-Aguilar J. Antiamoebic drugs for treating amoebic colitis. Cochrane Database Syst Rev. 2019 Jan 9. 1:CD006085. [QxMD MEDLINE Link].

  85. Singh A, Banerjee T, Shukla SK, Upadhyay S, Verma A. Creep in nitroimidazole inhibitory concentration among the Entamoeba histolytica isolates causing amoebic liver abscess and screening of andrographolide as a repurposing drug. Sci Rep. 2023 Jul 27. 13 (1):12192. [QxMD MEDLINE Link].

  86. Bammigatti C, Ramasubramanian NS, Kadhiravan T, Das AK. Percutaneous needle aspiration in uncomplicated amebic liver abscess: a randomized trial. Trop Doct. 2013 Jan. 43(1):19-22. [QxMD MEDLINE Link].

  87. Cordel H, Prendki V, Madec Y, Houze S, Paris L, Bourée P, et al. Imported amoebic liver abscess in France. PLoS Negl Trop Dis. 2013. 7 (8):e2333. [QxMD MEDLINE Link].

  88. Shrivastav MT, Malik Z, Somlata. Revisiting Drug Development Against the Neglected Tropical Disease, Amebiasis. Front Cell Infect Microbiol. 2020. 10:628257. [QxMD MEDLINE Link].

  89. McGregor A, Brown M, Thway K, Wright SG. Fulminant amoebic colitis following loperamide use. J Travel Med. 2007 Jan-Feb. 14 (1):61-2. [QxMD MEDLINE Link].

  90. Athié-Gutiérrez C, Rodea-Rosas H, Guízar-Bermúdez C, Alcántara A, Montalvo-Javé EE. Evolution of surgical treatment of amebiasis-associated colon perforation. J Gastrointest Surg. 2010 Jan. 14(1):82-7. [QxMD MEDLINE Link].

  91. Jha AK, Das G, Maitra S, Sengupta TK, Sen S. Management of large amoebic liver abscess--a comparative study of needle aspiration and catheter drainage. J Indian Med Assoc. 2012 Jan. 110(1):13-5. [QxMD MEDLINE Link].

  92. Chaudhry OA, Petri WA Jr. Vaccine prospects for amebiasis. Expert Rev Vaccines. 2005 Oct. 4(5):657-68. [QxMD MEDLINE Link].

  93. Snow MJ, Stanley SL Jr. Recent progress in vaccines for amebiasis. Arch Med Res. 2006 Feb. 37(2):280-7. [QxMD MEDLINE Link].

  94. Stanley SL Jr. Vaccines for amoebiasis: barriers and opportunities. Parasitology. 2006. 133 Suppl:S81-6. [QxMD MEDLINE Link].

  95. Quach J, St-Pierre J, Chadee K. The future for vaccine development against Entamoeba histolytica. Hum Vaccin Immunother. 2014 Feb 6. 10(6):[QxMD MEDLINE Link].

  96. Kikuchi T, Koga M, Shimizu S, Miura T, Maruyama H, Kimura M. Efficacy and safety of paromomycin for treating amebiasis in Japan. Parasitol Int. 2013 Dec. 62(6):497-501. [QxMD MEDLINE Link].

Author

Vinod K Dhawan, MD, FACP, FRCPC, FIDSA Clinical Professor, Department of Clinical Medicine, University of California, Los Angeles, David Geffen School of Medicine; Clinical Professor, Department of Clinical Medicine, Charles R Drew University of Medicine and Science

Vinod K Dhawan, MD, FACP, FRCPC, FIDSA is a member of the following medical societies: American College of Physicians, American Medical Association, American Society for Microbiology, Infectious Diseases Society of America, Royal College of Physicians and Surgeons of Canada

Disclosure: Nothing to disclose.

Coauthor(s)

J Robert Cantey, MD Professor, Department of Medicine, Division of Infectious Diseases, Medical University of South Carolina College of Medicine

J Robert Cantey, MD is a member of the following medical societies: Alpha Omega Alpha, American Society for Clinical Investigation, American Society for Microbiology, Infectious Diseases Society of America, International Society of Travel Medicine, Musculoskeletal Infection Society, Phi Beta Kappa, Southern Society for Clinical Investigation

Disclosure: Nothing to disclose.

Chief Editor

Michael Stuart Bronze, MD David Ross Boyd Professor and Chairman, Department of Medicine, Stewart G Wolf Endowed Chair in Internal Medicine, Department of Medicine, University of Oklahoma Health Science Center; Master of the American College of Physicians; Fellow, Infectious Diseases Society of America; Fellow of the Royal College of Physicians, London

Michael Stuart Bronze, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians, American Medical Association, Association of Professors of Medicine, Infectious Diseases Society of America, Oklahoma State Medical Association, Southern Society for Clinical Investigation

Disclosure: Nothing to disclose.

Acknowledgements

Michael Stuart Bronze, MD Professor, Stewart G Wolf Chair in Internal Medicine, Department of Medicine, University of Oklahoma Health Science Center

Michael Stuart Bronze, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians, American Medical Association, Association of Professors of Medicine, Infectious Diseases Society of America, Oklahoma State Medical Association, and Southern Society for Clinical Investigation

Disclosure: Nothing to disclose.

Vinod K Dhawan, MD, FACP, FRCP(C), FIDSA Professor, Department of Clinical Medicine, University of California, Los Angeles, David Geffen School of Medicine; Chief, Division of Infectious Diseases, Rancho Los Amigos National Rehabilitation Center

Vinod K Dhawan, MD, FACP, FRCP(C), FIDSA is a member of the following medical societies: American College of Physicians, American Society for Microbiology, American Society of Tropical Medicine and Hygiene, Infectious Diseases Society of America, and Royal College of Physicians and Surgeons of Canada

Disclosure: Pfizer Inc Honoraria Speaking and teaching

Maria A Horga, MD Assistant Professor, Department of Pediatric Infectious Diseases, Bristol-Myers Squibb

Disclosure: Nothing to disclose.

Alexandre Lacasse, MD, MSc Internal Medicine Faculty, Assistant Director, Medicine Clinic, Infectious Disease Consultant, St Mary's Health Center

Alexandre Lacasse, MD, MSc is a member of the following medical societies: American College of Physicians, American Medical Association, Association of Program Directors in Internal Medicine, Infectious Diseases Society of America, and Society for Healthcare Epidemiology of America

Disclosure: Nothing to disclose.

Klaus-Dieter Lessnau, MD, FCCP Clinical Associate Professor of Medicine, New York University School of Medicine; Medical Director, Pulmonary Physiology Laboratory; Director of Research in Pulmonary Medicine, Department of Medicine, Section of Pulmonary Medicine, Lenox Hill Hospital

Klaus-Dieter Lessnau, MD, FCCP is a member of the following medical societies: American College of Chest Physicians, American College of Physicians, American Medical Association, American Thoracic Society, and Society of Critical Care Medicine

Disclosure: Nothing to disclose.

Thomas R Naparst, MD Clinical Instructor in Emergency Medicine, New York University School of Medicine; Consulting Staff, Department of Emergency Medicine, New York Downtown Hospital

Thomas R Naparst, MD is a member of the following medical societies: American College of Emergency Physicians and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Michael D Nissen, MBBS, FRACP, FRCPA Associate Professor in Biomolecular, Biomedical Science & Health, Griffith University; Director of Infectious Diseases and Unit Head of Queensland Paediatric Infectious Laboratory, Sir Albert Sakzewski Viral Research Centre, Royal Children's Hospital

Michael D Nissen, MBBS, FRACP, FRCPA is a member of the following medical societies: American Academy of Pediatrics, American Society for Microbiology, Pediatric Infectious Diseases Society, Royal Australasian College of Physicians, and Royal College of Pathologists of Australasia

Disclosure: Nothing to disclose.

Russell W Steele, MD Head, Division of Pediatric Infectious Diseases, Ochsner Children's Health Center; Clinical Professor, Department of Pediatrics, Tulane University School of Medicine

Russell W Steele, MD is a member of the following medical societies: American Academy of Pediatrics, American Association of Immunologists, American Pediatric Society, American Society for Microbiology, Infectious Diseases Society of America, Louisiana State Medical Society, Pediatric Infectious Diseases Society, Society for Pediatric Research, and Southern Medical Association

Disclosure: Nothing to disclose.

Robert Swords, MD Fellow, Department of Medicine, Division of Infectious Diseases, Medical University of South Carolina

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Martin Weisse, MD Program Director, Associate Professor, Department of Pediatrics, West Virginia University

Martin Weisse, MD is a member of the following medical societies: Ambulatory Pediatric Association, American Academy of Pediatrics, and Pediatric Infectious Diseases Society

Disclosure: Nothing to disclose.

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.